NovoCure Ltd
Novocure Limited (Nasdaq: NVCR) is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), electric fields delivered by portable medical devices to disrupt cancer-cell division. Its products are Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and malignant… From the company’s description.
Over the twelve months to Sep 30, 2026, NovoCure Ltd reported revenue of $725.39M, up 12.9% from a year earlier, and a net loss of $121.73M. Its operating margin was −17.2%, and operations used $0.72M in cash. In fiscal 2025, it reported revenue of $655.35M, up 8.3% from fiscal 2024, and a net loss of $136.23M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NovoCure Ltd does
In the company’s own words
Novocure Limited (Nasdaq: NVCR) is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), electric fields delivered by portable medical devices to disrupt cancer-cell division. Its products are Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer. The devices use a field generator, skin-mounted arrays, batteries and accessories, and are generally used alongside standard cancer treatments. Novocure supplies products directly to patients in most markets, with hospitals serving as distribution partners in some countries; it also supports patients and caregivers and seeks reimbursement from public and private payers. The company markets products internationally and has granted Zai Lab rights to commercialize them in Greater China. Its research and clinical development programs study TTFields across several solid-tumor cancers, including brain metastases from lung cancer. As of December 31, 2025, Novocure had 217 sales force colleagues globally.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- ST. HELIER
- Fiscal year end
- December
- CIK
- 1645113
- SIC
- 3841
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NovoCure Ltd — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NovoCure Ltd’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NovoCure Ltd and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NovoCure Ltd's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NovoCure Ltd's last four quarterly filings that the numbers alone won't show?”